Janux Therapeutics Inc

JANX

Equity

ISIN null / Valor 111742522

NASDAQ (2025-11-21)

USD 28.80+0.73%

Janux Therapeutics Inc
UMushroom community rating:

3.57 37 votes No rating yet

NegativeNeutralPositive

About company

Janux Therapeutics Inc., founded in 2017, is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary technology to create next-generation T cell engagers designed to target and eliminate cancer cells while minimizing damage to healthy tissues. Janux successfully completed its initial public offering (IPO) in June 2021 and advanced its first therapeutic program to clinical trials in the latter half of 2022. The company's approach emphasizes a collaborative and data-driven culture to foster scientific innovation and accelerate the development of its therapeutic pipeline.

Summarized from source with an LLMView SourceSector: Healthcare

Strong Financial Position

As of June 30, 2025, Janux Therapeutics Inc maintained a healthy cash, cash equivalents, and short-term investments balance of $996.0 million, ensuring ample resources to support its ongoing and future initiatives.

Increased R&D Investments

Research and development expenses surged to $34.7 million in Q2 2025, up from $14.9 million in the same period last year, reflecting the company’s commitment to advancing its TRACTr, TRACIr, and ARM pipeline programs.

Ongoing Clinical Trials

Enrollment continues for JANX007 in its Phase 1 clinical trial for metastatic castration-resistant prostate cancer (mCRPC) and JANX008 for advanced or metastatic solid tumors. Updates on these trials are expected in the second half of 2025.

Milestone Payment from Merck

Janux Therapeutics Inc received a $10 million milestone payment from Merck following the dosing of the first patient in their lead collaboration program, underscoring the success of their strategic partnership.

Summarized from source with an LLMView Source

Key figures

-38.1%1Y

101%3Y

%5Y

Performance

76.6%1Y

103%3Y

97.7%5Y

Volatility